'An ounce of prevention is worth a pound of cure': The case for and against GnRH-agonist for fertility preservation

Annals of Oncology

Volumn 25, Issue 9, 2014, Pages 1719-1728

  Blumenfeld, Z ^a   Katz, G ^b   Evron, A ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fertility preservation; GnRH agonist; Gonadotoxicity; POF

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; GONADORELIN;

AGE DISTRIBUTION; AMENORRHEA; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; DISORDERS OF HORMONE METABOLISM; DRUG EFFICACY; DRUG RESPONSE; FERTILITY PRESERVATION; GONADOTOXICITY; HUMAN; NONHUMAN; OVARIAN RESERVE; OVARY FUNCTION; OVULATION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE SUCCESS; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION; ADULT; AGONISTS; DRUG EFFECTS; FEMALE; FERTILITY; MIDDLE AGED; NEOPLASMS; OVARY; PHYSIOLOGY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FERTILITY; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MIDDLE AGED; NEOPLASMS; OVARY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; YOUNG ADULT;

EID: 84906252454     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu036     Document Type: Review

References (62)

1. Georgescu ES, Goldberg JM, du Plessis SS et al. Present and future fertility preservation strategies for female cancer patients. Obstet Gynecol Surv 2008; 63: 725-732.
2. Jemal A, Bray F, Center M et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Blatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol 1999; 33: 29-33.
4. Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005; 6: 209-218.
5. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005; 353: 64-73.
6. Blumenfeld Z. Debate: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH-agonist in addition to cryopreservation of embryos, oocytes, or ovaries. Oncologist 2007; 12: 1044-1054.
7. Blumenfeld Z, von WolffM. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008; 14: 543-552.
8. Blumenfeld Z, Avivi I, Eckman R et al. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008; 89: 166-173.
9. Blumenfeld Z. GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabet Obes 2008; 15: 523-528.
10. Blumenfeld Z, Zuckerman T. Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist. Oncologist 2010; 15: 59-60.
11. Dolmans MM, Donnez J, Camboni A et al. IVF outcome in patients with orthotopically transplanted ovarian tissue. Hum Reprod 2009; 24: 2778-2787.
12. Dolmans MM, Marinescu C, Saussoy P et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010; 116: 2908-2914.
13. Rosendahl M, Andersen MT, Ralfkiær E et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94: 2186-2190.
14. Abir R, Feinmesser M, Yaniv I et al. Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod 2010; 25: 1708-1712.
15. Bittinger SE, Nazaretian SP, Gook DA et al. Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril 2011; 95: 803.e3-6.
16. Kyono K, Doshida M, Toya M et al. Potential indications for ovarian autotransplantation based on the analysis of 5,571 autopsy findings of females under the age of 40 in Japan. Fertil Steril 2010; 93: 2429-2430.
17. Del-Mastro L, Levaggi A, Giraudi A et al. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2011; 37: 208-211.
18. Del Mastro L, Giraudi S, Levaggi A et al. Medical approaches to preservation of fertility in female cancer patients. Expert Opin Pharmacother 2011; 12: 387-396. Review.
19. Clowse ME, Behera MA, Anders CK et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009; 18: 311-319.
20. Wong M, O'Neill S, Walsh G et al. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 2013; 24: 133-138.
21. Ben-Aharon I, Gafter-Gvili A, Leibovici L et al. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010; 122: 803-811.
22. Kim SS, Lee JR, Jee BC et al. Use of hormonal protection for chemotherapyinduced gonadotoxicity. Clin Obstet Gynecol 2010; 53: 740-752.
23. Bedaiwy MA, Abou-Setta AM, Desai N et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011; 95: 906-914.
24. Chen H, Li J, Cui T et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011: CD008018. doi:10.1002/14651858.CD008018.pub2.
25. Yang B, Shi W, Yang J et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 2013; 22: 150-157.
26. Wang C, Chen M, Fu F et al. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One 2013; 8: e66360. Print 2013.
27. Badawy A, Elnashar A, El-Ashry M et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697.
28. Ataya K, Rao LV, Lawrence E et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372.
29. Sverrisdottir A, Nystedt M, Johansson H et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117: 561-567.
30. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269-276.
31. Moore HC. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. American Society of Clinical Oncology 2008 Educational Book. Alexandria, VA: American Society of Clinical Oncology 2008; 39-42.
32. Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159-162.
33. Blumenfeld Z, Patel B, Leiba R et al. Gonadotropin releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. Fertil Steril 2012; 98: 1266-1270.
34. Azem F, Samara N, Cohen T et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease. J Assist Reprod Genet 2008; 25: 535-538.
35. Behringer K, Wildt L, Mueller H et al. German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010; 21: 2052-2060.
36. Behringer K, Thielen I, Mueller H et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012; 23: 1818-1825.
37. Demeestere I, Brice P, Peccatori FA et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013; 31: 903-909.
38. Gerber B, von Minckwitz G, Stehle H et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341.
39. Leonard RC, Adamson D, Anderson R et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010; 28(Suppl): 15s (abstr 590).
40. Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538.
41. Elgindy EA, El-Haieg DO, Khorshid OM et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86.
42. Recchia F, Candeloro G, Necozione S et al. Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy. Anticancer Res 2011; 31: 671-676.
43. Nitzschke M, Raddatz J, Bohlmann MK et al. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients. Arch Gynecol Obstet 2010; 282: 83-88.
44. Turner NH, Partridge A, Sanna G et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013; 24: 2224-2235.
45. Sukumvanich P, Case LD, Van Zee K et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010; 116: 3102-3111.
46. Chung K, Donnez J, Ginsburg E et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril 2013; 99: 1534-1542.
47. Fleisher LA, Bass EB, McKeown P. Methodological approach. American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128: 17S-23S.
48. Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. American Society of Clinical Oncology. J Clin Oncol 2013; 31: 2500-2510.
49. Remérand G, Merlin E, Froissart R et al. Four successful pregnancies in a patient with mucopolysaccharidosis type I treated by allogeneic bone marrow transplantation. J Inherit Metab Dis 2009; 32(Suppl 1): S111-S113.
50. Salooja N, Szydlo RM, Socie G et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001; 358: 271-276.
51. Carter A, Robison LL, Francisco L et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006; 37: 1023-1029.
52. Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98: 890-896.
53. Green DM, Sklar CA, Boice JD et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2374-2381.
54. Edgar AB, Wallace WH. Pregnancy in women who had cancer in childhood. Eur J Cancer 2007; 43: 1890-1894.
55. Partridge A, Gelber S, Gelber RD et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43: 1646-1653.
56. Cuzick J, Ambroisine L, Davidson N et al. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711-1723.
57. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
58. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
59. Meirow D, Rabinovici J, Katz D et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormonereleasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006; 107: 1634-1641.
60. von WolffM, Montag M, Dittrich R et al. Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011; 284: 427-435.
61. Demeestere P, Brice FA, Peccatori et al. Triptorelin to prevent chemotherapy-induced ovarian failure in lymphoma patients: a prospective randomized study. [abstr].
62. Del Mastro L, Ceppi M, Poggio F et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2013 [epub ahead of print].